{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Nintedanib+%28BIBF+1120%29", "query": { "intervention": "Nintedanib (BIBF 1120)" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 70, "total_pages": 7, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Nintedanib+%28BIBF+1120%29&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-10-03T05:17:43.645Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02399215", "title": "Nintedanib in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Carcinoid Tumor", "Metastatic Carcinoid Tumor", "Neuroendocrine Neoplasm" ], "interventions": [ { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Nintedanib", "type": "DRUG" }, { "name": "Pharmacological Study", "type": "OTHER" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" } ], "intervention_types": [ "OTHER", "DRUG" ], "sponsor": "Roswell Park Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 32, "start_date": "2015-05-15", "completion_date": "2022-08-31", "has_results": true, "last_update_posted_date": "2023-12-26", "last_synced_at": "2026-10-03T05:17:43.645Z", "location_count": 2, "location_summary": "Buffalo, New York • Columbus, Ohio", "locations": [ { "city": "Buffalo", "state": "New York" }, { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT02399215" }, { "nct_id": "NCT01335477", "title": "Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients II", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Pulmonary Fibrosis" ], "interventions": [ { "name": "placebo", "type": "DRUG" }, { "name": "BIBF 1120", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": null, "sex": "ALL", "summary": "40 Years and older" }, "enrollment_count": 551, "start_date": "2011-05", "completion_date": "2013-10", "has_results": true, "last_update_posted_date": "2016-07-25", "last_synced_at": "2026-10-03T05:17:43.645Z", "location_count": 27, "location_summary": "Scottsdale, Arizona • San Francisco, California • Santa Barbara, California + 23 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "San Francisco", "state": "California" }, { "city": "Santa Barbara", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Torrance", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01335477" }, { "nct_id": "NCT02902484", "title": "Study of Nintedanib and Chemotherapy for Advanced Pancreatic Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Cancer of Pancreas" ], "interventions": [ { "name": "Nintedanib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Texas Southwestern Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 14, "start_date": "2017-09-07", "completion_date": "2021-10-26", "has_results": true, "last_update_posted_date": "2024-06-03", "last_synced_at": "2026-10-03T05:17:43.645Z", "location_count": 1, "location_summary": "Dallas, Texas", "locations": [ { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02902484" }, { "nct_id": "NCT01619085", "title": "Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Idiopathic Pulmonary Fibrosis" ], "interventions": [ { "name": "Nintedanib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": null, "sex": "ALL", "summary": "40 Years and older" }, "enrollment_count": 752, "start_date": "2012-06-06", "completion_date": "2021-02-01", "has_results": true, "last_update_posted_date": "2022-03-25", "last_synced_at": "2026-10-03T05:17:43.645Z", "location_count": 37, "location_summary": "Jasper, Alabama • Phoenix, Arizona • Los Angeles, California + 34 more", "locations": [ { "city": "Jasper", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Santa Barbara", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01619085" }, { "nct_id": "NCT02234596", "title": "Nintedanib in Patients With Advanced Esophagogastric Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Esophagogastric Adenocarcinoma" ], "interventions": [ { "name": "Nintedanib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 34, "start_date": "2014-09-04", "completion_date": "2020-04-22", "has_results": true, "last_update_posted_date": "2021-01-25", "last_synced_at": "2026-10-03T05:17:43.645Z", "location_count": 6, "location_summary": "Basking Ridge, New Jersey • Middletown, New Jersey • Commack, New York + 3 more", "locations": [ { "city": "Basking Ridge", "state": "New Jersey" }, { "city": "Middletown", "state": "New Jersey" }, { "city": "Commack", "state": "New York" }, { "city": "Harrison", "state": "New York" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02234596" }, { "nct_id": "NCT01225887", "title": "Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Endometrial Adenocarcinoma", "Endometrial Clear Cell Adenocarcinoma", "Endometrial Mucinous Adenocarcinoma", "Endometrial Serous Adenocarcinoma", "Endometrial Squamous Cell Carcinoma", "Endometrial Transitional Cell Carcinoma", "Endometrial Undifferentiated Carcinoma", "Malignant Uterine Corpus Mixed Epithelial and Mesenchymal Neoplasm", "Recurrent Uterine Corpus Carcinoma" ], "interventions": [ { "name": "Nintedanib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gynecologic Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 37, "start_date": "2011-10", "completion_date": "2016-01", "has_results": true, "last_update_posted_date": "2017-10-09", "last_synced_at": "2026-10-03T05:17:43.645Z", "location_count": 59, "location_summary": "Burbank, California • Aurora, Colorado • Hartford, Connecticut + 40 more", "locations": [ { "city": "Burbank", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Hartford", "state": "Connecticut" }, { "city": "Savannah", "state": "Georgia" }, { "city": "Boise", "state": "Idaho" } ], "official_url": "https://clinicaltrials.gov/study/NCT01225887" }, { "nct_id": "NCT01380782", "title": "BIBF 1120 for Recurrent High-Grade Gliomas", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Glioblastoma", "Gliosarcoma", "Anaplastic Astrocytoma", "Anaplastic Oligodendroglioma", "Anaplastic Oligoastrocytoma" ], "interventions": [ { "name": "BIBF 1120", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Patrick Y. Wen, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 37, "start_date": "2012-05", "completion_date": "2014-07", "has_results": true, "last_update_posted_date": "2014-08-18", "last_synced_at": "2026-10-03T05:17:43.645Z", "location_count": 4, "location_summary": "Boston, Massachusetts • Cleveland, Ohio • Charlottesville, Virginia", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Cleveland", "state": "Ohio" }, { "city": "Charlottesville", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT01380782" }, { "nct_id": "NCT02299141", "title": "Nintedanib in Molecularly Selected Patients With Advanced Non-Small Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Carcinoma, Non-Small-Cell Lung", "Non-Small Cell Lung Cancer", "Nonsmall Cell Lung Cancer" ], "interventions": [ { "name": "Nintedanib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2015-05-07", "completion_date": "2025-04-23", "has_results": true, "last_update_posted_date": "2025-06-24", "last_synced_at": "2026-10-03T05:17:43.645Z", "location_count": 1, "location_summary": "St Louis, Missouri", "locations": [ { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT02299141" }, { "nct_id": "NCT01948141", "title": "Nintedanib in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Failed Up to Two Previous Chemotherapy Regimens", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Recurrent Non-small Cell Lung Cancer", "Squamous Cell Lung Cancer", "Stage III Non-small Cell Lung Cancer", "Stage IV Non-small Cell Lung Cancer" ], "interventions": [ { "name": "nintedanib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Roswell Park Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 6, "start_date": "2014-01-30", "completion_date": "2016-08-16", "has_results": true, "last_update_posted_date": "2017-06-08", "last_synced_at": "2026-10-03T05:17:43.645Z", "location_count": 2, "location_summary": "Buffalo, New York • Cleveland, Ohio", "locations": [ { "city": "Buffalo", "state": "New York" }, { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT01948141" }, { "nct_id": "NCT03958071", "title": "A Study Based on Medical Records That Looks at the Characteristics of Idiopathic Pulmonary Fibrosis Patients Grouped by the Type of Medication They Are Taking", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Idiopathic Pulmonary Fibrosis" ], "interventions": [ { "name": "Nintedanib", "type": "DRUG" }, { "name": "Pirfenidone", "type": "DRUG" }, { "name": "Untreated Cohort", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": null, "sex": "ALL", "summary": "40 Years and older" }, "enrollment_count": 13264, "start_date": "2019-02-01", "completion_date": "2019-05-31", "has_results": true, "last_update_posted_date": "2021-11-15", "last_synced_at": "2026-10-03T05:17:43.645Z", "location_count": 1, "location_summary": "Plymouth, Pennsylvania", "locations": [ { "city": "Plymouth", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT03958071" } ] }